Equities Analysts Offer Predictions for ResMed Q3 Earnings

ResMed Inc. (NYSE:RMD - Free Report) - Equities research analysts at Zacks Research cut their Q3 2026 earnings per share estimates for shares of ResMed in a report released on Monday, April 14th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.48 per share for the quarter, down from their prior forecast of $2.50. The consensus estimate for ResMed's current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed's Q3 2027 earnings at $2.68 EPS.

RMD has been the subject of a number of other research reports. Citigroup upgraded ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday, March 5th. KeyCorp boosted their price target on shares of ResMed from $266.00 to $280.00 and gave the company an "overweight" rating in a report on Friday, January 31st. UBS Group raised shares of ResMed from a "hold" rating to a "strong-buy" rating in a research note on Friday, January 31st. The Goldman Sachs Group initiated coverage on shares of ResMed in a research note on Thursday, January 16th. They set a "buy" rating on the stock. Finally, StockNews.com raised ResMed from a "hold" rating to a "buy" rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $251.00.

ResMed Price Performance

Shares of NYSE:RMD traded up $1.40 on Wednesday, reaching $212.89. 1,109,562 shares of the company traded hands, compared to its average volume of 1,024,057. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. The stock has a market capitalization of $31.27 billion, a PE ratio of 25.13, a P/E/G ratio of 1.53 and a beta of 0.75. The company's 50 day moving average is $223.12 and its 200-day moving average is $234.52. ResMed has a fifty-two week low of $176.92 and a fifty-two week high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last released its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.

ResMed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th were given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.00%. The ex-dividend date of this dividend was Thursday, February 13th. ResMed's payout ratio is 25.03%.

Insider Buying and Selling at ResMed

In related news, Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the transaction, the director now directly owns 77,218 shares of the company's stock, valued at approximately $18,695,249.98. This trade represents a 2.52 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael J. Farrell sold 8,009 shares of the company's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $236.77, for a total value of $1,896,290.93. Following the sale, the chief executive officer now directly owns 455,472 shares of the company's stock, valued at $107,842,105.44. The trade was a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 49,013 shares of company stock worth $11,298,816 over the last three months. Corporate insiders own 0.71% of the company's stock.

Institutional Trading of ResMed

Several hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in shares of ResMed by 23,982.6% in the first quarter. GAMMA Investing LLC now owns 733,556 shares of the medical equipment provider's stock valued at $164,207,000 after acquiring an additional 730,510 shares during the period. Invesco Ltd. boosted its holdings in ResMed by 32.2% in the 4th quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock valued at $531,706,000 after purchasing an additional 566,046 shares during the period. Norges Bank bought a new stake in ResMed in the 4th quarter valued at $118,605,000. Captrust Financial Advisors grew its position in ResMed by 813.4% in the 4th quarter. Captrust Financial Advisors now owns 443,340 shares of the medical equipment provider's stock worth $101,387,000 after purchasing an additional 394,803 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in shares of ResMed by 133.6% during the 4th quarter. AQR Capital Management LLC now owns 625,054 shares of the medical equipment provider's stock worth $142,944,000 after purchasing an additional 357,466 shares during the period. Institutional investors own 54.98% of the company's stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.